Ricerca avanzata

Home > Riviste > Minerva Endocrinologica > Fascicoli precedenti > Minerva Endocrinologica 2015 Giugno;40(2) > Minerva Endocrinologica 2015 Giugno;40(2):119-28



Rivista sulle Malattie del Sistema Endocrino

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118

Periodicità: Trimestrale

ISSN 0391-1977

Online ISSN 1827-1634


Minerva Endocrinologica 2015 Giugno;40(2):119-28


Bariatric surgery: to whom and when?

Benaiges D. 1, 2, 3, Goday A. 1, 2, 3, 4, Pedro-Botet J. 1, 2, 3, Más A. 1, Chillarón J. J. 1, 2, 3, Flores-Le Roux J. A. 1, 2, 3

1 Department of Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain;
2 Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain;
3 Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain;
4 CiberOBN, Instituto de Salud Carlos III, Barcelona, Spain

Bariatric surgery is the most effective treatment for obesity. Its effects go beyond weight loss, in a high percentage of cases achieving remission of comorbidities associated with obesity and reducing mortality. However, not all patients achieve satisfactory weight loss or resolution of comorbidities and perioperative complications are a constant risk. Correct preoperative evaluation is essential to predict the likelihood of success and choose the most appropriate surgical technique for this purpose. The aim of this review was to ascertain which obese subjects will benefit from bariatric surgery taking into account body mass index, age, comorbidities, risk of complications and the impact of different bariatric surgery techniques.

lingua: Inglese


inizio pagina